Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonlicromanol - Khondrion

Next Previous
Drug Profile

Sonlicromanol - Khondrion

Alternative Names: KH 176

Latest Information Update: 24 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Khondrion
  • Class Antiparkinsonians; Benzopyrans; Piperidines; Small molecules
  • Mechanism of Action Prostaglandin-E synthase inhibitors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - MELAS syndrome; Leigh disease; Mitochondrial disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Mitochondrial disorders
  • No development reported Parkinson's disease

Most Recent Events

  • 29 Jan 2026 Phase-III clinical trials in Mitochondrial disorders in Netherlands, United Kingdom (PO) (NCT06451757)
  • 22 Dec 2025 Khondrion plans a phase II trial in Post acute COVID-19 syndrome in February 2026 (PO) (NCT07298005)
  • 14 May 2025 Khondrion plans a pivotal phase III trial in Mitochondrial disorders (PO) in 2H-2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top